1,566
Views
5
CrossRef citations to date
0
Altmetric
Articles

Epidemiology of trachoma and its implications for implementing the “SAFE” strategy in Somali Region, Ethiopia: results of 14 population-based prevalence surveys

, , , , , , , , , , , , & show all
 

ABSTRACT

Purpose: Ethiopia is highly trachoma endemic. Baseline mapping was needed in Ethiopia’s Somali Region to guide elimination efforts.

Methods: Cross-sectional community-based surveys were conducted in 34 suspected trachoma-endemic woredas, grouped as 14 evaluation units (EUs), using a standardised mapping methodology developed for the Global Trachoma Mapping Project.

Results: In total, 53,467 individuals were enumerated. A total of 48,058 (89.9%) were present at the time of survey teams’ visits and consented to examination. The prevalence of trachomatous inflammation–follicular (TF) among children aged 1–9 years ranged from 4.1% in the EU covering Danot, Boh, and Geladin woredas in Doolo Subzone to 38.1% in the EU covering Kebribeyah and Hareshen woredas in Fafan Subzone (East). The trichiasis prevalence among adults aged over 15 years varied from 0.1% in the EU covering Afder, Bare, and Dolobay woredas in Afder Subzone (West) to 1.2% in the EU covering Awbere in Fafan Subzone (West).

Conclusion: Mass drug administration (MDA) with azithromycin is needed in 13 EUs (population 2,845,818). Two EUs (population 667,599) had TF prevalences in 1–9-year-olds of ≥30% and will require at least 5 years of MDA; 5 EUs (population 1,1193,032) had TF prevalences of 10–29.9% and need at least three years of MDA; 6 EUs (population 985,187) had TF prevalences of 5–9.9% and need at least one round of azithromycin distribution before re-survey. In all 13 of these EUs, implementation of facial cleanliness and environmental improvement measures is also needed. Surveys are still needed in the remaining 34 unmapped woredas of Somali Region.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Funding

This study was principally funded by the Global Trachoma Mapping Project (GTMP) grant from the United Kingdom’s Department for International Development (ARIES: 203145) to Sightsavers, which led a consortium of non-governmental organisations and academic institutions to support ministries of health to complete baseline trachoma mapping worldwide. The GTMP was also funded by the United States Agency for International Development (USAID), through the ENVISION project implemented by RTI International under cooperative agreement number AID-OAA-A-11-00048, and the END in Asia project implemented by FHI360 under cooperative agreement number OAA-A-10-00051. A committee established in March 2012 to examine issues surrounding completion of global trachoma mapping was initially funded by a grant from Pfizer to the International Trachoma Initiative. AWS was a Wellcome Trust Intermediate Clinical Fellow (098521) at the London School of Hygiene & Tropical Medicine. None of the funders had any role in project design, in project implementation or analysis or interpretation of data, in the decisions on where, how or when to publish in the peer reviewed press, or in preparation of the manuscript.

Additional information

Notes on contributors

Ahmed Badei Duale

ABD oversaw field work, interpreted the data, and drafted the manuscript. NNA and RW analysed the data. BK reviewed the data. RMF provided key geographical information system input. CKM, MD, and AWS designed the sampling and analysis and provided technical oversight; AWS is Chief Scientist to the GTMP. ABK, WA, and PAM trained the survey teams. All authors reviewed the draft manuscript critically for intellectual content, and read and approved the final version.